• Abstract and Figures
• Public Full-text

Dear Shareholders, ǨǦǧǯDžîƙîNjĚîƑūIJƙĿijŠĿǛČîŠƥîČČūŞƎŕĿƙĺŞĚŠƥƙIJūƑ¡ūƑƥūŕîîƙDžĚŞîēĚƥĺĚƥƑîŠƙĿƥĿūŠƥū îijŕūċîŕČūŞŞĚƑČĿîŕūƑijîŠĿǕîƥĿūŠȦ~ƭƑǜîijƙĺĿƎŞĚēĿČĿŠĚȡŠēĚNJNJî® ȱČūîijƭŕîƥĿūŠIJîČƥūƑÝî ȳƑĚČūŞċĿŠîŠƥȴȡĿŠîČƥĿDŽîƥĚēȹǕĺǕūȲȡĿƙŠūDžîDŽîĿŕîċŕĚƥūĺūƙƎĿƥîŕƙîŠēƎîƥĿĚŠƥƙĿŠƥĺĚÀŠĿƥĚē¬ƥîƥĚƙ îŠēîijƑūDžĿŠijŠƭŞċĚƑūIJ/ƭƑūƎĚîŠČūƭŠƥƑĿĚƙȦØĚîČĺĿĚDŽĚēƙĚDŽĚƑîŕŕîŠēŞîƑŒŞĿŕĚƙƥūŠĚƙIJūƑŠēĚNJNJî îŠē~ŠēĚNJNJNjîʆȳîŠēĚNJîŠĚƥîŕIJîȫƥĺĚƥƑîēĚŠîŞĚIJūƑŠēĚNJNJîĿŠ/ƭƑūƎĚȴƥĺîƥDžĿŕŕēƑĿDŽĚƥĺĚIJƭƥƭƑĚijƑūDžƥĺ ūIJƥĺĚČūŞƎîŠNjîŠēƙƭƎƎūƑƥūƭƑDŽĿƙĿūŠƥūēĚŕĿDŽĚƑŕĿIJĚȹƙîDŽĿŠijƥƑĚîƥŞĚŠƥƙIJūƑƙĚƑĿūƭƙċŕūūēȹƑĚŕîƥĚēēĿƙūƑēĚƑƙȦ U.S. COMMERCIAL LAUNCH ÀŠĿƥĚēeĿŠijēūŞîŠēƥĺĚƑǕŠĚĿŞĿƥƥĚŕŞîƑŒƥȹ ƥĺĚijŕūċîŕ ~×T'ȹǧǯƎîŠēĚŞĿČȡDžĺĿČĺĺîƙ OF ANDEXXA sĚƭūƑēŠƭŠijƙijĚƙĚƥǕȳqs~HȴĿŠHĚƑŞîŠNjȡ ČĺîŠijĚēîŕŕîƙƎĚČƥƙūIJūƭƑēîĿŕNjŕĿDŽĚƙîŠēƥĺĚ îŕŕūDžĿŠijIJūƑĿŠĿƥĿîŕƙîŕĚƙĿŠƥĺĚƙĚĿŞƎūƑƥîŠƥ DžîNjĿŠDžĺĿČĺDžĚČūŠēƭČƥċƭƙĿŠĚƙƙȦƙDžĚ ǨǦǧǯDžîƙƥĺĚǛƑƙƥIJƭŕŕNjĚîƑūIJƥĺĚŠēĚNJNJî ŞîƑŒĚƥƙĿŠƥĺĚƙĚČūŠēĺîŕIJūIJǨǦǧǯîŠēƙĚƥƥĿŠij ŠîDŽĿijîƥĚƥĺƑūƭijĺƥĺĿƙƎîŠēĚŞĿČȡ¡ūƑƥūŕîɄƙǛƑƙƥ ŕîƭŠČĺĿŠƥĺĚÀȦ¬ȦIJūŕŕūDžĿŠijƥĺĚîƎƎƑūDŽîŕūIJ ƥĺĚƙƥîijĚIJūƑƑĚĿŞċƭƑƙĚŞĚŠƥČūDŽĚƑîijĚ ƎƑĿūƑĿƥNjĿƙƥĺĚĺĚîŕƥĺîŠēƙîIJĚƥNjūIJĚŞƎŕūNjĚĚƙȡ ūƭƑƙĚČūŠēȹijĚŠĚƑîƥĿūŠŞîŠƭIJîČƥƭƑĿŠijƎƑūČĚƙƙ decisions in 2020. ƎîƥĿĚŠƥƙîŠēĺĚîŕƥĺČîƑĚƎƑūDŽĿēĚƑƙȦØĚĺîDŽĚ ƥîŒĚŠƎƑūîČƥĿDŽĚƙƥĚƎƙƥūŞĿƥĿijîƥĚƥĺĚƙƎƑĚîē ūŠ'ĚČĚŞċĚƑǩǧȡǨǦǧǮȦ~DŽĚƑƥĺĚČūƭƑƙĚūIJƥĺĚ ØĚîƑĚĚNJČĿƥĚēƥūŞūDŽĚČŕūƙĚƑƥūŞîŒĿŠij ūIJƥĺĚDŽĿƑƭƙDžĺĿŕĚîŕƙūDžūƑŒĿŠijƥūƎƑūDŽĿēĚ NjĚîƑȡDžĚîēēĚēǪǨǫŠĚDžĺūƙƎĿƥîŕČƭƙƥūŞĚƑƙIJūƑ ~ŠēĚNJNJNjîîDŽîĿŕîċŕĚƥūƎîƥĿĚŠƥƙĿŠƥĺĚƙĚŞîƑŒĚƥƙ ƭŠĿŠƥĚƑƑƭƎƥĚēƙƭƎƎūƑƥƥūĚŠƙƭƑĚƥĺîƥĺūƙƎĿƥîŕƙ îƥūƥîŕūIJǬǪǦĺūƙƎĿƥîŕƙƥĺîƥĺîDŽĚŠūDžūƑēĚƑĚē îŠēƥĺĚƑĚƙƥūIJ/ƭƑūƎĚȡIJƭƑƥĺĚƑĚNJƎîŠēĿŠijîČČĚƙƙ ČîŠČūŠƥĿŠƭĚƥūƭƙĚîŠēƑĚȹūƑēĚƑŠēĚNJNJîIJūƑ ŠēĚNJNJîĿŠƥĺĚÀȦ¬Ȧ¹ūijĚƥĺĚƑȡDžĚĚƙƥĿŞîƥĚƥĺîƥ ƥūƥĺĚǛƑƙƥîŠēūŠŕNjîƎƎƑūDŽĚēƑĚDŽĚƑƙîŕîijĚŠƥ ƎîƥĿĚŠƥƙƥîŒĿŠijƑĿDŽîƑūNJîċîŠūƑîƎĿNJîċîŠƥĺîƥ ƥĺĚƙĚĺūƙƎĿƥîŕƙƭƥĿŕĿǕĚēŠēĚNJNJîƥūƥƑĚîƥūDŽĚƑ IJūƑƎîƥĿĚŠƥƙƥîŒĿŠijƑĿDŽîƑūNJîċîŠūƑîƎĿNJîċîŠȦ ǪȡǦǦǦƎîƥĿĚŠƥƙDžĿƥĺGîČƥūƑÝîĿŠĺĿċĿƥūƑȹƑĚŕîƥĚē ĚNJƎĚƑĿĚŠČĚŕĿIJĚȹƥĺƑĚîƥĚŠĿŠijċŕĚĚēƙȦ ċŕĚĚēĿŠijĿŠǨǦǧǯȦ STRATEGIC FOCUS ON ANDEXXA ƙDžĚŕūūŒîĺĚîēȡƥĺĚƑĚĿƙƙĿijŠĿǛČîŠƥŕūŠijȹƥĚƑŞ ØĚċĚŕĿĚDŽĚƥĺĚƑĚĿƙîƙĿijŠĿǛČîŠƥūƎƎūƑƥƭŠĿƥNjƥū ijƑūDžƥĺūƎƎūƑƥƭŠĿƥNjIJūƑŠēĚNJNJîȦØĚƎŕîŠƥū ĿŞƎƑūDŽĚūƭƥČūŞĚƙIJūƑŞūƑĚūIJƥĺĚƙĚƎîƥĿĚŠƥƙȶ 'ƭƑĿŠijƥĺĚNjĚîƑȡDžĚČūŠƥĿŠƭĚēƥūĿŠDŽĚƙƥĿŠ ēĚĚƎĚŠƭƙĚĿŠƥĺĚÀȦ¬ȦȡĚNJƎîŠēijĚūijƑîƎĺĿČîŕŕNj îDŽĿĚDžƥĺîƥĿƙƭŠēĚƑƙČūƑĚēċNjƥĺĚƑĚČūŞŞĚŠēîƥĿūŠ DžūƑŕēȹČŕîƙƙČîƎîċĿŕĿƥĿĚƙîŠēƥîŕĚŠƥîČƑūƙƙ ĿŠ/ƭƑūƎĚȡîŠēċƑūîēĚŠƥĺĚŠēĚNJNJîŕîċĚŕ ƥūƭƙĚŠēĚNJNJîūƑîƙƎĚČĿǛČƑĚDŽĚƑƙîŕîijĚŠƥċNj ƙîŕĚƙȡēĚDŽĚŕūƎŞĚŠƥȡƐƭîŕĿƥNjȡŞîƑŒĚƥîČČĚƙƙȡ DžĿƥĺîēēĿƥĿūŠîŕGîČƥūƑÝîĿŠĺĿċĿƥūƑƙîŠēîŠ ǧǯŞĚēĿČîŕƙūČĿĚƥNjijƭĿēĚŕĿŠĚƙĿŠƥĺĚÀŠĿƥĚē ŞĚēĿČîŕîIJIJîĿƑƙîŠēċƭƙĿŠĚƙƙĿŠIJūƑŞîƥĿūŠƥū ĿŠēĿČîƥĿūŠIJūƑƎîƥĿĚŠƥƙDžĺūƑĚƐƭĿƑĚƭƑijĚŠƥ ¬ƥîƥĚƙîŠē/ƭƑūƎĚîƙDžĚŕŕîƙijƭĿēĚŕĿŠĚƙIJƑūŞ ƙƭƎƎūƑƥƥĺĚŕîƭŠČĺūIJŠēĚNJNJîȦ¹ĺĿƙĿŠČŕƭēĚƙ ƙƭƑijĚƑNjȦØĚƑĚŞîĿŠƙƥĚîēIJîƙƥĿŠūƭƑĚIJIJūƑƥƙƥū ¹ĺĚcūĿŠƥ ūŞŞĿƙƙĿūŠȡƥĺĚŠîƥĿūŠɄƙūŕēĚƙƥîŠē ĚNJƎîŠēĿŠijūƭƑÀȦ¬ȦƙîŕĚƙƥĚîŞȡĚƙƥîċŕĿƙĺĿŠij ĚēƭČîƥĚƥĺĚĺĚîŕƥĺČîƑĚČūŞŞƭŠĿƥNjDžĿƥĺČŕĿŠĿČîŕ ŕîƑijĚƙƥƙƥîŠēîƑēƙȹƙĚƥƥĿŠijîŠēîČČƑĚēĿƥĿŠijċūēNj ūƭƑ/ƭƑūƎĚîŠŕĚîēĚƑƙĺĿƎîŠēČūƭŠƥƑNjȹŕĚDŽĚŕ îŠēĚČūŠūŞĿČēîƥîƥĺîƥČŕĚîƑŕNjēĚŞūŠƙƥƑîƥĚƙ in healthcare. ƥĚîŞƙȡîŠēȡĿŠGĚċƑƭîƑNjǨǦǨǦȡDžĚŕČūŞĿŠijūƭƑ GîČƥūƑÝîĿŠĺĿċĿƥūƑƎîƥĿĚŠƥƙƙĺūƭŕēūŠŕNjċĚ ŠĚDžČĺĿĚIJŞĚēĿČîŕūIJǛČĚƑȡDžĺūDžĿŕŕēƑĿDŽĚƥĺĚ ijĿDŽĚŠŠēĚNJNJîDžĺĚŠîŠƭŠČūŠƥƑūŕŕĚēūƑŕĿIJĚȹ TŠūƑēĚƑƥūîČĺĿĚDŽĚċƑūîēĚƑîēūƎƥĿūŠȡ ČŕĿŠĿČîŕēĚDŽĚŕūƎŞĚŠƥîŠēŕĿIJĚČNjČŕĚŞîŠîijĚŞĚŠƥ ƥĺƑĚîƥĚŠĿŠijċŕĚĚēĿŠijĚDŽĚŠƥūČČƭƑƙȦ DžĚîƑĚĚNJĚČƭƥĿŠijîƙƥƑîƥĚijĿČƎŕîŠƥūēĚDŽĚŕūƎ ƙƥƑîƥĚijNjIJūƑŠēĚNJNJîȦŕƙūĿŠĚîƑŕNjǨǦǨǦȡ TŠČŕūƙĿŠijȡūƭƑƙƭČČĚƙƙIJƭŕŕîƭŠČĺîŠēƎƑūijƑĚƙƙ and disseminate clinical, health economic and DžĚƥūūŒĿŞƎūƑƥîŠƥƙƥĚƎƙƥūîŕĿijŠūƭƑIJūČƭƙ ĿŠǨǦǧǯDžūƭŕēŠūƥċĚƎūƙƙĿċŕĚDžĿƥĺūƭƥƥĺĚ ūƥĺĚƑēîƥîƥĺîƥĺĿijĺŕĿijĺƥƥĺĚDŽîŕƭĚūIJŠēĚNJNJî îŠēƑĚƙūƭƑČĚƙūŠĚNJƎîŠēĿŠijƥĺĚŠēĚNJNJî ƎîƥĿĚŠƥƙîŠēĺĚîŕƥĺČîƑĚƎƑūIJĚƙƙĿūŠîŕƙƥĺîƥ ČūŞƎîƑĚēƥūūƥĺĚƑŠūŠȹƙƎĚČĿǛČƥĺĚƑîƎĿĚƙƥĺîƥ ČƭƙƥūŞĚƑċîƙĚîŠēēƑĿDŽĿŠijƭƥĿŕĿǕîƥĿūŠ ƎîƑƥĿČĿƎîƥĚĿŠūƭƑČŕĿŠĿČîŕƥƑĿîŕƙȡƥĺĚîČîēĚŞĿČ ĺĿƙƥūƑĿČîŕŕNjĺîDŽĚċĚĚŠƭƙĚēūIJIJȹŕîċĚŕIJūƑƥĺĚƙĚ DžĿƥĺĺūƙƎĿƥîŕČƭƙƥūŞĚƑƙȦ ƎîƥĿĚŠƥƙȦØĚċĚijîŠƎƑĚƙĚŠƥĿŠijƥĺĿƙēîƥîĿŠ îŠēČŕĿŠĿČîŕƎîƑƥŠĚƑƙDžĺūČūŕŕîċūƑîƥĚDžĿƥĺ ǨǦǧǯîŠēĺîDŽĚîƑūċƭƙƥƙČĺĚēƭŕĚūIJŠĚDžēîƥî ØĚČūŞƎŕĚƥĚēîŠĿŠƥĚƑŠîŕƑĚƙƥƑƭČƥƭƑĿŠijƥū ƭƙȡƥĺĚDžĿƙĚČūƭŠƙĚŕūIJūƭƑūîƑēūIJ'ĿƑĚČƥūƑƙ ƎŕĚēIJūƑǨǦǨǦîŠēċĚNjūŠēȦ¹ĺĿƙĿƙċîČŒĚē ƑĚēƭČĚƙƎĚŠēĿŠijūŠƑĚƙĚîƑČĺƎƑūijƑîŞƙîŠē îŠēƥĺĚūŠijūĿŠijƙƭƎƎūƑƥūIJūƭƑƙĺîƑĚĺūŕēĚƑƙȦ ċNjūƭƑĚēƭČîƥĿūŠîŕîŠēƙƭƎƎūƑƥƎƑūijƑîŞƙ IJūČƭƙūƭƑƑĚƙūƭƑČĚƙūŠƥĺĚŠēĚNJNJîƑĚDŽĚŠƭĚ ~ŠċĚĺîŕIJūIJƥĺĚĚŠƥĿƑĚ¡ūƑƥūŕîĚNJĚČƭƥĿDŽĚƥĚîŞ îƑūƭŠēŠēĚNJNJîɄƙŠĚDžƥĚČĺŠūŕūijNjîēēȹūŠ ēƑĿDŽĚƑƙîŠēŕĿIJĚČNjČŕĚŞîŠîijĚŞĚŠƥȦƙîƑĚƙƭŕƥȡ îŠēūƭƑūîƑēūIJ'ĿƑĚČƥūƑƙȡƥĺNjūƭIJūƑNjūƭƑ ƎîNjŞĚŠƥȳs¹¡ȴIJƑūŞƥĺĚ ĚŠƥĚƑƙIJūƑqĚēĿČîƑĚ DžĚēĿƙČūŠƥĿŠƭĚēūƭƑĚIJIJūƑƥƙƥūČūŞŞĚƑČĿîŕĿǕĚ ČūŠƥĿŠƭĚēċĚŕĿĚIJĿŠūƭƑŞĿƙƙĿūŠȦ ʁqĚēĿČîĿē¬ĚƑDŽĿČĚƙȳ q¬ȴîŠēƑĚĿŞċƭƑƙĚŞĚŠƥ ūƑƎîƑƥŠĚƑĚDŽNjNJNJîʅȳċĚƥƑĿNJîċîŠȴîŠēƎîƭƙĚē ċĚƙƥƎƑîČƥĿČĚƙȦ ƥĺĚĿŠĿƥĿîƥĿūŠūIJƥĺĚ /g¹T ȹǧƥƑĿîŕIJūƑūƭƑ¬ÞeȬ ceĿŠĺĿċĿƥūƑȡČĚƑēƭŕîƥĿŠĿċȡƭŠƥĿŕDžĚƙĚČƭƑĚ ¬ĿŠČĚƑĚŕNjȡ EUROPEAN APPROVAL AND îēĚDŽĚŕūƎŞĚŠƥƎîƑƥŠĚƑȦ LAUNCH OF ONDEXXYA ¡ūƑƥūŕîDžĿŕŕČūŠƥĿŠƭĚƥūIJūČƭƙūŠƥĺĚIJūƭŠēîƥĿūŠ ūIJūƭƑċƭƙĿŠĚƙƙȡDžĺĿČĺĿƙƥūIJƭĚŕƥĺĚŠĚîƑȹƥĚƑŞ ~ŠēĚNJNJNjîƑĚČĚĿDŽĚēŞîƑŒĚƥĿŠijîƭƥĺūƑĿǕîƥĿūŠ îŠēIJƭƥƭƑĚijƑūDžƥĺūIJŠēĚNJNJîîŠēēƑĿDŽĚ IJƑūŞƥĺĚ/ƭƑūƎĚîŠ ūŞŞĿƙƙĿūŠĿŠƎƑĿŕǨǦǧǯȦ ƙĺîƑĚĺūŕēĚƑDŽîŕƭĚċNjDžūƑŒĿŠijƥūDžîƑēūƭƑDŽĿƙĿūŠ /ƭƑūƎĚƑĚƎƑĚƙĚŠƥƙîŕîƑijĚîŠēijƑūDžĿŠij ƥūċĚċĚƙƥȹĿŠȹČŕîƙƙĿŠƥĺĚƥƑĚîƥŞĚŠƥūIJƙĚƑĿūƭƙ Scott Garland ūƎƎūƑƥƭŠĿƥNjȡDžĿƥĺîƎƎƑūNJĿŞîƥĚŕNjēūƭċŕĚ blood-related disorders. ƥĺĚŠƭŞċĚƑūIJGîČƥūƑÝîĿŠĺĿċĿƥūƑƎîƥĿĚŠƥƙ ČūŞƎîƑĚēƥūƥĺĚÀȦ¬ȦØĚŞîēĚĿŞƎūƑƥîŠƥ ƎƑūijƑĚƙƙĿŠċƭĿŕēĿŠijîŠĚIJǛČĿĚŠƥ/ƭƑūƎĚîŠ ANDEXXA POISED FOR GROWTH ċƭƙĿŠĚƙƙĿŠūƭƑØîDŽĚǧČūƭŠƥƑĿĚƙūIJHĚƑŞîŠNjȡ IN 2020 AND BEYOND ƭƙƥƑĿîȡƥĺĚÀŠĿƥĚēeĿŠijēūŞȡƥĺĚsĚƥĺĚƑŕîŠēƙȡ ¬DžĚēĚŠȡ'ĚŠŞîƑŒîŠēGĿŠŕîŠēȦ ǨǦǨǦDžĿŕŕċĚîŠĿŞƎūƑƥîŠƥNjĚîƑūIJĚNJĚČƭƥĿūŠȡ ijƑūDžƥĺîŠēĚNJƎîŠƙĿūŠIJūƑŠēĚNJNJîîijîĿŠƙƥ TŞƎūƑƥîŠƥŕNjȡƙĺūƑƥŕNjîIJƥĚƑîƎƎƑūDŽîŕȡūƭƑƥĚîŞ ƥĺĚċîČŒēƑūƎūIJƥĺĚŕîƑijĚîŠēijƑūDžĿŠijGîČƥūƑ ƙƭċŞĿƥƥĚēēūƙƙĿĚƑƙƥūƥĺĚsîƥĿūŠîŕTŠƙƥĿƥƭƥĚ ÝîĿŠĺĿċĿƥūƑŞîƑŒĚƥȦƥƥĺĚƙîŞĚƥĿŞĚȡDžĚ IJūƑOĚîŕƥĺîŠē îƑĚ/NJČĚŕŕĚŠČĚȳsT /ȴĿŠƥĺĚ îƑĚūƎĚƑîƥĿŠijĿŠƭŠƎƑĚČĚēĚŠƥĚēƥĿŞĚƙDžĿƥĺ PORTOLA PHARMACEUTICALS ANNUAL REPORT 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-K ____________________________________________________ (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35935 ____________________________________________________ PORTOLA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ____________________________________________________ Delaware 20-0216859 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 270 E. Grand Avenue South San Francisco, California 94080 (Address of Principal Executive Offices) (Zip Code) (650) 246-7000 (Registrant’s Telephone Number, Including Area Code) ____________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.001 per share PTLA The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $1.1 billion computed by reference to the last sales price of $27.13 as reported by the Nasdaq Global Select Market, as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2019. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose. As of February 20, 2020, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 78,080,365. DOCUMENTS INCORPORATED BY REFERENCE Part III incorporates information by reference to the definitive proxy statement for the registrant’s 2019 Annual Meeting of Stockholders to be filed within 120 days of the registrant’s fiscal year ended December 31, 2019. TABLE OF CONTENTS Portola Pharmaceuticals, Inc. Form 10-K Index Page Part I Item 1. Business 3 Item 1A. Risk Factors 15 Item 1B. Unresolved Staff Comments 41 Item 2. Properties 41 Item 3. Legal Proceedings 41 Item 4. Mine Safety Disclosures 41 Part II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer

Load more

  112

Copy Link